NCT06246110
A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC
Active, Not Recruiting
PHASE2Ages 18+InterventionalTreatmentEikon Therapeutics
~70 participants
Updated 2026-05-28 on ClinicalTrials.gov
What's tested:EIK1001PembrolizumabPaclitaxelPemetrexedCarboplatin
At a glance
Recruiting sites
0 of 38 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Percentage of participants with safety event during treatment
Measured over Up to 2 years
Conditions
Where it's being run
38 sites across 19 statesCalifornia5
New York5
Florida4
Texas3
Virginia3
Illinois2
Kansas2
Maryland2
Study leadership
- Etah Kurland, MD · STUDY_DIRECTOR · Eikon Therapeutics
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- Percentage of participants with safety event during treatmentUp to 2 years
Defined AEs that occur during treatment and are deemed to be related EIK1001 or combination with SOC or due to disease progression or toxicity.